Multidisciplinary focus on methotrexate in psoriatic disesase

Antonio Marchesoni, Massimo Ricci, Erica Moggio, Valeria Brazzelli, Giovanni Borroni

Research output: Contribution to journalArticle


The aim of this focus is to establish the role of methotrexate (MTX) in the treatment of psoriatic disease (PD). Despite the lack of hard evidence, MTX can be regarded as the nonbiological drug of choice for the treatment of peripheral psoriatic arthritis, although its effect on psoriatic dactylitis, enthesitis, and spondylitis needs to be further studied by means of well conducted clinical trials.MTX is effective in improving the skin involvement of PD, and can be used in moderate to severe psoriasis before starting a biological agent. Although rheumatologists consider it relatively safe in PD, dermatologists are very concerned about its toxicity and so, until more definite data are available, precautions should be taken to prevent MTX-induced liver fibrosis and cirrhosis.

Original languageEnglish
Pages (from-to)56-58
Number of pages3
JournalJournal of Rheumatology
Issue numberSUPPL. 83
Publication statusPublished - Aug 2009


  • Hepatotoxicity
  • Methotrexate
  • Psoriatic arthritis
  • Psoriatic disease

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)
  • Immunology and Allergy
  • Rheumatology

Fingerprint Dive into the research topics of 'Multidisciplinary focus on methotrexate in psoriatic disesase'. Together they form a unique fingerprint.

  • Cite this